This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graham, M. A. Articles by Gamelin, E. Search for Related Content PubMed PubMed Citation Articles by Graham, M. A. Articles by Gamelin, E.

Clinical Pharmacokinetics of Oxaliplatin: A Critical Review

Department of Clinical Pharmacokinetics and Drug Metabolism, Sanofi-Synthelabo Research, Malvern, Pennsylvania 19355 [M. A. G., G. F. L., D. G.]; Debiopharm SA, 1003 Lausanne, Switzerland [S. B., M. B.]; and Center Paul Papin, 49033 Angers, France [E. G.]

ABSTRACT

Oxaliplatin (cis-[(1R,2R)-1,2-cyclohexanediamine-N,N'] oxalato(2-)-O,O'] platinum; Eloxatine) is a novel platinum coordination complex used for the treatment of metastatic colorectal carcinoma in combination with fluoropyrimidines. The objective of this review is to integrate the key data from multiple studies into a single, comprehensive overview of oxaliplatin disposition in cancer patients. The pharmacokinetics (PKs) of unbound platinum in plasma ultrafiltrate after oxaliplatin administration was triphasic, characterized by a short initial distribution phase and a long terminal elimination phase (t_1/2, 252–273 h). No accumulation was observed in plasma ultrafiltrate after 130 mg/m² every 3 weeks or 85 mg/m² every 2 weeks. Interpatient and intrapatient variability in platinum exposure (area under the curve_0–48) is moderate to low (33 and 5% respectively). In the blood, platinum binds irreversibly to plasma proteins (predominantly serum albumin) and erythrocytes. Accumulation of platinum in blood cells is not considered to be clinically significant. Platinum is rapidly cleared from plasma by covalent binding to tissues and renal elimination. Urinary excretion (53.8 ± 9.1%) was the predominant route of platinum elimination, with fecal excretion accounting for only 2.1 ± 1.9% of the administered dose 5 days postadministration. Tissue binding and renal elimination contribute equally to the clearance of ultrafilterable platinum from plasma. Renal clearance of platinum significantly correlated with glomerular filtration rate, indicating that glomerular filtration is the principal mechanism of platinum elimination by the kidneys. Clearance of ultrafilterable platinum is lower in patients with moderate renal impairment; however, no marked increase in drug toxicity was reported. The effect of severe renal impairment on platinum clearance and toxicity is currently unknown. Covariates such as age, sex, and hepatic impairment had no significant effect on the clearance of ultrafilterable platinum, and dose adjustment due to these variables is not required. Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation and is not subjected to CYP450-mediated metabolism. Up to 17 platinum-containing products have been observed in plasma ultrafiltrate samples from patients. These include several proximate cytotoxic species, including the monochloro-, dichloro-, and diaquo-diaminocyclohexane platinum complexes, along with several other noncytotoxic products. Oxaliplatin does not inhibit CYP450 isoenzymes in vitro. Platinum was not displaced from plasma proteins by a variety of concomitant medications tested in vitro, and no marked PK interactions between oxaliplatin, 5-fluorouracil, and irinothecan have been observed. These results indicate that the additive/synergistic antitumor activity observed with these agents is not due to major alterations in drug exposure, and the enhanced efficacy is likely to be mechanistically based. Together, these PK, biotransformation, drug-drug interaction analyses and studies in special patient populations provide a firm scientific basis for the safe and effective use of oxaliplatin in the clinic. These analyses also reveal that the pharmacological activity of oxaliplatin may be attributable, at least in part, to the unique pattern of platinum disposition observed in patients.

This article has been cited by other articles:

				S. M. Lichtman Pharmacology of Antineoplastic Agents for Older Patients ASCO Educational Book, January 1, 2008; 2008(1): 210 - 214. [Abstract] [Full Text] [PDF]

				P. Andre, S. Cisternino, A.-L. Roy, F. Chiadmi, J. Schlatter, P. Agranat, O. Fain, and J.-E. Fontan Stability of oxaliplatin in infusion bags containing 5% dextrose injection Am. J. Health Syst. Pharm., September 15, 2007; 64(18): 1950 - 1954. [Abstract] [Full Text] [PDF]

				C. H. Takimoto, M. A. Graham, G. Lockwood, C. M. Ng, A. Goetz, D. Greenslade, S. C. Remick, S. Sharma, S. Mani, R. K. Ramanathan, et al. Oxaliplatin Pharmacokinetics and Pharmacodynamics in Adult Cancer Patients with Impaired Renal Function Clin. Cancer Res., August 15, 2007; 13(16): 4832 - 4839. [Abstract] [Full Text] [PDF]

				K. Shitara, M. Munakata, O. Muto, R. Okada, S. Mitobe, M. Mino, I. Ikami, and Y. Sakata Hepatic Arterial Infusion of Oxaliplatin for a Patient with Hepatic Metastases from Colon Cancer Undergoing Hemodialysis Jpn. J. Clin. Oncol., August 4, 2007; (2007) hym044v1. [Abstract] [Full Text] [PDF]

				T. W. Synold, C. H. Takimoto, J. H. Doroshow, D. Gandara, S. Mani, S. C. Remick, D. L. Mulkerin, A. Hamilton, S. Sharma, R. K. Ramanathan, et al. Dose-Escalating and Pharmacologic Study of Oxaliplatin in Adult Cancer Patients with Impaired Hepatic Function: A National Cancer Institute Organ Dysfunction Working Group Study Clin. Cancer Res., June 15, 2007; 13(12): 3660 - 3666. [Abstract] [Full Text] [PDF]

				S. L. Spunt, B. B. Freeman III, C. A. Billups, V. McPherson, R. B. Khan, C. B. Pratt, and C. F. Stewart Phase I Clinical Trial of Oxaliplatin in Children and Adolescents With Refractory Solid Tumors J. Clin. Oncol., June 1, 2007; 25(16): 2274 - 2280. [Abstract] [Full Text] [PDF]

				S. M. Lichtman, H. Wildiers, E. Chatelut, C. Steer, D. Budman, V. A. Morrison, B. Tranchand, I. Shapira, and M. Aapro International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of Chemotherapy in Older Patients--An Analysis of the Medical Literature J. Clin. Oncol., May 10, 2007; 25(14): 1832 - 1843. [Abstract] [Full Text] [PDF]

				A. J. Gelibter, S. Di Segni, M. Zeuli, M. Milella, G. Ferretti, C. Nuzzo, and F. Cognetti Old Age: Biologic Versus Chronologic J. Clin. Oncol., February 20, 2007; 25(6): e8 - e8. [Full Text] [PDF]

				L. Markasz, G. Stuber, B. Vanherberghen, E. Flaberg, E. Olah, E. Carbone, S. Eksborg, E. Klein, H. Skribek, and L. Szekely Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells Mol. Cancer Ther., February 1, 2007; 6(2): 644 - 654. [Abstract] [Full Text] [PDF]

				K. Shirao, Y. Matsumura, Y. Yamada, K. Muro, M. Gotoh, N. Boku, A. Ohtsu, F. Nagashima, Y. Sano, M. Mutoh, et al. Phase I Study of Single-Dose Oxaliplatin in Japanese Patients with Malignant Tumors Jpn. J. Clin. Oncol., May 1, 2006; 36(5): 295 - 300. [Abstract] [Full Text] [PDF]

				J. R. Rice, J. L. Gerberich, D. P. Nowotnik, and S. B. Howell Preclinical Efficacy and Pharmacokinetics of AP5346, A Novel Diaminocyclohexane-Platinum Tumor-Targeting Drug Delivery System. Clin. Cancer Res., April 1, 2006; 12(7): 2248 - 2254. [Abstract] [Full Text] [PDF]

				P. Pfeiffer, H. Sorbye, H. Ehrsson, T. Fokstuen, J. P. Mortensen, L. Baltesgard, K. M. Tveit, D. Ogreid, H. Starkhammar, I. Wallin, et al. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil Ann. Onc., February 1, 2006; 17(2): 252 - 258. [Abstract] [Full Text] [PDF]

				S. S. Jacobs, E. Fox, C. Dennie, L. B. Morgan, C. L. McCully, and F. M. Balis Plasma and Cerebrospinal Fluid Pharmacokinetics of Intravenous Oxaliplatin, Cisplatin, and Carboplatin in Nonhuman Primates Clin. Cancer Res., February 15, 2005; 11(4): 1669 - 1674. [Abstract] [Full Text] [PDF]

				R. J Cersosimo Oxaliplatin-Associated Neuropathy: A Review Ann. Pharmacother., January 1, 2005; 39(1): 128 - 135. [Abstract] [Full Text] [PDF]

				S. Hector, C. W. Porter, D. L. Kramer, K. Clark, J. Prey, N. Kisiel, P. Diegelman, Y. Chen, and L. Pendyala Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase Mol. Cancer Ther., July 1, 2004; 3(7): 813 - 822. [Abstract] [Full Text] [PDF]

				A. Ballestrero, A. Nencioni, D. Boy, I. Rocco, A. Garuti, G. S. Mela, L. Van Parijs, P. Brossart, S. Wesselborg, and F. Patrone Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Cooperates with Anticancer Drugs to Overcome Chemoresistance in Antiapoptotic Bcl-2 Family Members Expressing Jurkat Cells Clin. Cancer Res., February 15, 2004; 10(4): 1463 - 1470. [Abstract] [Full Text] [PDF]

				R. L. Hayward, J. S. Macpherson, J. Cummings, B. P. Monia, J. F. Smyth, and D. I. Jodrell Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect Mol. Cancer Ther., February 1, 2004; 3(2): 169 - 178. [Abstract] [Full Text] [PDF]

				E. H. Lim, R. S. C. Lim, T. S. Wu, and H. L. Kong Oxaliplatin/Fluorouracil/Leucovorin in Advanced Colorectal Carcinoma: an Asian Experience Ann. Pharmacother., December 1, 2003; 37(12): 1909 - 1912. [Abstract] [Full Text] [PDF]

				M. P. Goetz, C. Erlichman, A. J. Windebank, J. M. Reid, J. A. Sloan, P. Atherton, A. A. Adjei, J. Rubin, H. Pitot, E. Galanis, et al. Phase I and Pharmacokinetic Study of Two Different Schedules of Oxaliplatin, Irinotecan, Fluorouracil, and Leucovorin in Patients With Solid Tumors J. Clin. Oncol., October 15, 2003; 21(20): 3761 - 3769. [Abstract] [Full Text] [PDF]

				C. H. Takimoto, S. C. Remick, S. Sharma, S. Mani, R. K. Ramanathan, J. Doroshow, A. Hamilton, D. Mulkerin, M. Graham, G. F. Lockwood, et al. Dose-Escalating and Pharmacological Study of Oxaliplatin in Adult Cancer Patients With Impaired Renal Function: A National Cancer Institute Organ Dysfunction Working Group Study J. Clin. Oncol., July 15, 2003; 21(14): 2664 - 2672. [Abstract] [Full Text] [PDF]

				G. Masci, M. Magagnoli, P. A. Zucali, L. Castagna, C. Carnaghi, B. Sarina, V. Pedicini, M. Fallini, and A. Santoro Minidose Warfarin Prophylaxis for Catheter-Associated Thrombosis in Cancer Patients: Can It Be Safely Associated With Fluorouracil-Based Chemotherapy? J. Clin. Oncol., February 15, 2003; 21(4): 736 - 739. [Abstract] [Full Text] [PDF]

				D. Mavroudis, P. Pappas, C. Kouroussis, S. Kakolyris, S. Agelaki, K. Kalbakis, N. Androulakis, J. Souglakos, N. Vardakis, M. Nikolaidou, et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors Ann. Onc., February 1, 2003; 14(2): 304 - 312. [Abstract] [Full Text] [PDF]

				N. Kemeny, W. Tong, M. Gonen, J. Stockman, C. Di Lauro, J. Teitcher, P. White, C. Price, L. Saltz, S. Sharma, et al. Phase I study of weekly oxaliplatin plus irinotecan in previously treated patients with metastatic colorectal cancer Ann. Onc., September 1, 2002; 13(9): 1490 - 1496. [Abstract] [Full Text] [PDF]

				J.-M. Gornet, E. Savier, F. Lokiec, E. Cvitkovic, J. -L. Misset, and F. Goldwasser Exacerbation of oxaliplatin neurosensory toxicity following surgery Ann. Onc., August 1, 2002; 13(8): 1315 - 1318. [Abstract] [Full Text] [PDF]

				L. Zelek, P. Cottu, M. Tubiana-Hulin, J.-M. Vannetzel, Ph. Chollet, J.-L. Misset, N. Chouaki, M. Marty, E. Gamelin, S. Culine, et al. Phase II Study of Oxaliplatin and Fluorouracil in Taxane- and Anthracycline-Pretreated Breast Cancer Patients J. Clin. Oncol., May 15, 2002; 20(10): 2551 - 2558. [Abstract] [Full Text] [PDF]

				R. H. Wilson, T. Lehky, R. R. Thomas, M. G. Quinn, M. K. Floeter, and J. L. Grem Acute Oxaliplatin-Induced Peripheral Nerve Hyperexcitability J. Clin. Oncol., April 1, 2002; 20(7): 1767 - 1774. [Abstract] [Full Text] [PDF]

				D. Elias, M. Bonnay, J. M. Puizillou, S. Antoun, S. Demirdjian, A. El Otmany, J. P. Pignon, L. Drouard-Troalen, J. F. Ouellet, and M. Ducreux Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution Ann. Onc., February 20, 2002; 13(2): 267 - 272. [Abstract] [Full Text] [PDF]

				E. Raymond, S. Faivre, S. Chaney, J. Woynarowski, and E. Cvitkovic Cellular and Molecular Pharmacology of Oxaliplatin Mol. Cancer Ther., January 1, 2002; 1(3): 227 - 235. [Abstract] [Full Text] [PDF]

				F. E. de Jongh, J. Verweij, W. J. Loos, R. de Wit, M. J.A. de Jonge, A. S.T. Planting, K. Nooter, G. Stoter, and A. Sparreboom Body-Surface Area-Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure J. Clin. Oncol., September 1, 2001; 19(17): 3733 - 3739. [Abstract] [Full Text] [PDF]